CTOs on the Move

AsclepiX Therapeutics

www.asclepix.com

 
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.asclepix.com
  • 185 Hudson Street Suite 2500
    Jersey City, NJ USA 07311
  • Phone: N/A

Executives

Name Title Contact Details

Funding

AsclepiX Therapeutics raised $35M on 06/24/2020

Similar Companies

B-Bridge International

B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encoded Therapeutics

Encoded Therapeutics Inc. is a biotechnology company advancing precision medicines for a broad range of genetic disorders. Our mission is to unlock new opportunities for viral gene therapy through genomics-driven discovery. We focus on delivering life-changing advances for individuals with genetic disorders not addressable with current approaches.

Cresilon Inc

Recognizing the importance of managing a traumatic bleed quickly and effectively, Joe Landolina and Isaac Miller founded Cresilon, Inc. based on the hemostatic plant-based gel technology Joe invented while experimenting in the lab. Cresilon has since grown into a biotechnology company headquartered in Brooklyn, New York, commercializing our medical device technology in the animal health, trauma care, and surgical markets.

Provivi

We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.

Casma Therapeutics

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.